FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
US security agency is using Anthropic’s Mythos despite blacklist, Axios reports
IRNA from Under the current circumstances, it does not appear that there is a clear horizon...
Iranian media: Tehran has not yet finalized its participation in new talks with the United...
Bank Debate Interview: Umar Farooq and Shahmir Khaliq
U.S. Attorney: Detained Iranian Woman Involved in Brokering Sale of Drones, Bombs, and Millions of...
U.S. authorities announce the arrest of an Iranian businesswoman on charges of involvement in deals...
QXO to Buy TopBuild in $17 Billion Building Products Deal
IRAN REJECTED TAKING PART IN THE SECOND ROUND OF THE TALKS WITH THE U.S. - IRAN'S IRNA...
AST SpaceMobile Comments on BlueBird 7 Launch
Streaming Industry Leader Maintains Strong Performance in 2026
Woodside Energy Reports New Oil Discovery at Bandit-1 Site
JPMorgan Initiates Coverage of ResMed with Overweight Rating and Price Target
Survey Reveals Shift in Perception of Fast Food Value Among Americans
Analysts Remain Bullish on Block, Inc. Amid Growth Projections
NSA Utilizes Anthropic's Mythos Model Amid Pentagon Supply Chain Concerns
8 CHILDREN KILLED IN A MASS SHOOTING IN SHREVEPORT, LOUISIANA, SAY POLICE - NBC...
Anwar Gargash: It is not possible to return to the previous pace in relations with Iran without...
Anwar Gargash: It is unacceptable to accept congestion, threats, and aggression as a new...
Wall Street Analysts Predict Shift from Chip Stocks to Software Investments
Five Underrated AI Stocks Identified as Potential Winners by 2026
Michael Saylor Sparks Speculation of New Bitcoin Acquisition
Novartis Stock Attracts Investor Interest Amid Recent Price Movements
Rising Electricity Bills Concern Middle-Class Households
Iranian Officials Express Concerns Over Potential U.S. Military Action
Anwar Gargash: It is not possible to return to the previous pace in relations with Iran without a...
Anwar Gargash: For us in the UAE, the Iranian aggression against the states and peoples of the...
Blue Origin Rocket Stumbles on First Commercial Mission
Blue Origin Successfully Reuses Heavy Rocket in Space Milestone
Memory Specialist Expected to Outperform Major Tech Companies by 2027
Lebanese Army: We removed an earthen barrier placed by the Israeli occupation yesterday on the...
Iran rejects second round of talks, suspects possible U.S. attack - report
Israeli Army: Combat teams continue their operations south of Lebanon south of the forward defense...
Israeli Army: Elimination of more than 250 Hezbollah elements in southern Lebanon...
Public Companies with Largest Bitcoin Holdings Revealed
Iran Declines to Engage in Second Round of U.S. Negotiations
Trump to Fox News: Iran has already agreed to many of the deal's provisions...
QXO to buy commercial roofing firm TopBuild for $17 billion
Netflix Share Price Dip Seen as Opportunity for Long-Term Investors
Global Power Grids Embrace Large-Scale Battery Installations
Deere Settles $99 Million Lawsuit Amid Ongoing Farmer Concerns
Home Depot Offers Competitive Salaries Across All Levels
Verizon CEO Highlights AI's Disruptive Impact on Employment
Netanyahu: We are in a war against Iran, which spreads instability in the world, and we have no...
Steve Jobs's Hatred For This Computer Part Led To One Of Apple's Biggest Tech Failures Of All Time — But MacBook Neo Finally Perfects His Vision
Trump to Fox News: If Iran does not sign an agreement, the entire country will be destroyed...
Economic impact of Iran war will hurt US even after conflict ends, economists warn
Nvidia's Market Cap Falls Below $5 Trillion but Recovery Expected
Palo Alto Networks and Sandisk Show Promising Growth Potential
Transportation Secretary Predicts Lower Air Travel Costs Post-War
AbbVie to Present Phase 2 Data for Mirvetuximab Soravtansine-gynx at SGO 2026
AbbVie has announced that it will present late-breaking results from the Phase 2 IMGN853-0420 trial at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting, scheduled for April 10-13, 2026, in San Juan, Puerto Rico. This study focuses on the efficacy and safety of mirvetuximab soravtansine-gynx, a first-in-class antibody-drug conjugate, in treating patients with platinum-sensitive ovarian cancer.
The trial investigates the use of mirvetuximab soravtansine-gynx in combination with carboplatin, followed by maintenance therapy with mirvetuximab soravtansine-gynx alone. This approach aims to enhance treatment outcomes for patients diagnosed with this challenging form of cancer. The presentation will provide insights into the potential benefits of this innovative therapy.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News